From treatment to threat: the fatal impact of cumulative glucocorticoid dosage on outcomes in immunocompromised patients with community-acquired pneumonia.

ABSTRACT:

Background

Chronic glucocorticoid therapy is known to heighten the risk of secondary pulmonary infections. However, the impact of cumulative glucocorticoid dosage (CGD) on mortality risk in patients who develop community-acquired pneumonia (CAP) while undergoing glucocorticoid therapy remains inadequately explored.

Objectives

This study aims to clarify the relationship between CGD and mortality outcomes in immunocompromised patients with CAP.

Design

This study is a retrospective cohort analysis utilizing data from the DRYAD database.

Methods

We examined data from 561 patients diagnosed with CAP who had received either oral or intravenous glucocorticoids prior to their CAP diagnosis. To evaluate the effect of CGD on mortality risk, we employed piecewise linear r

SUBMITTER: Wang S 

PROVIDER: S-EPMC12033499 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature